Duchenne Muscular Dystrophy Stocks
Biopharmaceutical developers in this space focus on addressing the genetic loss of functional dystrophin through exon-skipping therapies, gene replacement, and small molecule interventions designed to preserve muscle integrity.
As of Oct 23, 2026, Duchenne Muscular Dystrophy has 11 US-listed companies worth $17.2B combined. The median member moved +1.6% over the past week; DYN led at +9.6% and CAPR trailed at -11.6%.
Companies in Duchenne Muscular Dystrophy
- PTCT – PTC Therapeutics Inc, $5.3B
- EWTX – Edgewise Therapeutics Inc, $4.3B
- DYN – Dyne Therapeutics Inc, $2.9B
- SRPT – Sarepta Therapeutics Inc, $1.8B
- WVE – Wave Life Sciences Ltd, $745M
- SLDB – Solid Biosciences LLC, $737M
- RGNX – Regenxbio Inc, $473M
- CAPR – Capricor Therapeutics Inc, $384M
- TRDA – Entrada Therapeutics Inc, $209M
- PEPG – PepGen Ltd, $166M
- MSLE – Satellos Bioscience Inc. Common Stock, $145M